DNA Sequencing Market Size, Share, Forecast, & Trends Analysis by Offering (Kits & Reagents [DNA Extraction, Library Preparation, QC], Instruments, Software), Technology (NGS, Sanger), Application (Clinical, Research) End User

Description

List of Tables

DNA Sequencing Market Size, Share, Forecast, & Trends Analysis by Offering (Kits & Reagents [DNA Extraction, Library Preparation, QC], Instruments, Software), Technology (NGS, Sanger), Application (Clinical, Research) End User-Global Forecast to 2031

The global DNA sequencing market is projected to reach $21.30 billion by 2031 at a CAGR of 11.8% from 2024 to 2031.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities.

The DNA sequencing market's growth is driven by several factors, including the decreasing costs of sequencing, the rising incidence of cancer and genetic disorders, the rising use of DNA sequencing in diagnostics and personalized medicine, increased pharmaceutical R&D investments, favorable regulatory and reimbursement policies, high healthcare expenditures, advances in sequencing technology, and supportive government initiatives aimed at promoting the use of sequencing technology in clinical & research applications. However, factors such as the high cost of sequencing consumables, limited identification of actionable mutations for precision medicine, and ethical and legal concerns related to DNA sequencing-based diagnostics restrain this growth.

Moreover, the expanding applications of DNA sequencing, government support for extensive genomic projects, growing awareness and adoption of targeted therapies, and economic growth in emerging markets are anticipated to offer growth opportunities for companies operating in this market. However, regulatory uncertainties, limited expertise & sequencing capabilities among smaller laboratories, a shortage of sequencing professionals in developing regions, and the substantial capital required for NGS infrastructure are some of the challenges impeding the market's growth.

Key trends in this market include the focus of emerging DNA sequencing companies on technological advancements and cost reduction and the emphasis by major players on developing portable and real-time sequencing technologies.

The report offers a competitive landscape based on an extensive assessment of the key players' product portfolios and geographical presence and the key growth strategies adopted by them over the past few years (2021-2024). The key players operating in the global DNA sequencing market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Revvity, Inc. (U.S.), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Danaher Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K.), and MGI Tech Co., Ltd. (China).

Among the offerings studied in this report, in 2024, the consumables segment is projected to dominate the DNA sequencing market, capturing 73.4% of the total share. The significant market share is attributed to the growing demand for consumables from end users, frequent use of sample preparation materials, increasing affordability, and the expansion of genome mapping programs.

Among the applications studied in this report, in 2024, the research & other applications segment is projected to dominate the DNA sequencing market, capturing 67.2% of the total share. The significant market share is attributed to several factors: the declining cost of sequencing procedures, increased R&D investments by pharmaceutical and biotechnology companies in drug discovery, the expanding use of NGS in various clinical and research settings, and the application of informatics solutions to identify pharmacological targets, validate therapeutic hypotheses, and assess the potential safety of inhibitory compounds targeting molecular sites.

Among the end users studied in this report, in 2024, the pharmaceutical & biotechnology companies segment is projected to dominate the DNA sequencing market, capturing 44.7% of the total share. The significant market share is attributed to increased R&D expenditures by pharmaceutical & biotechnology companies and the growing prevalence of chronic diseases, which are fueling the adoption of next-generation sequencing products.

An in-depth analysis of the geographical scenario of the global DNA sequencing market provides detailed qualitative and quantitative insights into five major regions (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2024, North America is projected to dominate the market, capturing 49.0% of the total share. Additionally, in 2024, the U.S. is expected to dominate the DNA sequencing market in North America. The region's significant market share can be attributed to several factors, including supportive government initiatives for genomic research, expanding applications of sequencing-based studies, the presence of leading next-generation sequencing technology providers, rising research investments by pharmaceutical and biopharmaceutical companies, decreasing sequencing costs, wide availability of advanced sequencing products and solutions, increasing cancer prevalence, and a favorable reimbursement environment in the region.

Scope of the Report:

DNA Sequencing Market Assessment-by Offering

Consumables
- Sample Preparation Kits & Reagents
DNA Extraction & Amplification
Quality Control
Other Kits & Reagents
- Other Consumables
Instruments
Software
Services

Note: Other Kits & Reagents Include dilution buffers, DNA standards, reagents for DNA cleanup, target enrichment, and other reagents

DNA Sequencing Market Assessment -by Technology

Next-Generation Sequencing
- Sequencing by Synthesis
- Ion Semiconductor Sequencing
- DNA Nanoball Sequencing
- Single-molecule Real-time Sequencing
- Other NGS Technologies
Sanger Sequencing & Pyrosequencing

Note: Other NGS Technologies Nanopore Sequencing and AVITI Sequencing

DNA Sequencing Market Assessment -by Application

Research & Other Applications
- Drug Discovery
- Agriculture & Animal Research
- Other Applications
Clinical Applications
- Reproductive Health
- Oncology
- Infectious Diseases
- Other Clinical Applications

Note: Other Applications include food microbiology, microbiota analysis in the beverage industry, and environmental studies.

Note: Other Clinical Applications include the detection of genetic aberrations in neurological disorders, rare diseases, and metabolic and immune disorders.

DNA Sequencing Market Assessment-by End User

Pharmaceutical & Biotechnology Companies
Hospitals & Diagnostic Laboratories
Academic Institutes & Research Centers
Other End Users

Note: Other End Users include forensic laboratories & security agencies, food & beverage companies, and agriculture companies.

DNA Sequencing Market Assessment-by Geography

North America
- U.S.
- Canada
Europe
- Germany
- France
- Italy
- U.K.
- Spain
- Rest of Europe (RoE)
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific (RoAPAC)
Latin America
- Brazil
- Mexico
- Rest of Latin America (RoLATAM)
Middle East & Africa

Product Code: MRHC - 1041309

1. Introduction

1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders

2. Research Methodology

2.1. Research Process
2.2. Process of Data Collection & Validation
- 2.2.1. Secondary Research
- 2.2.2. Primary Research/Interviews with Key Opinion Leaders of The Industry
2.3. Market Sizing and Forecast
- 2.3.1. Market Size Estimation Approach
- 2.3.2. Growth Forecast Approach
- 2.3.3. Market Share Analysis
2.4. Assumptions for the Study

3. Executive Summary

4. Market Insights

4.1. Overview
4.2. Factors Affecting Market Growth
- 4.2.1. Impact Analysis of Market Dynamics
- 4.2.2. Factor Analysis
4.3. Pricing Analysis
4.4. Industry Trends
- 4.4.1. Emerging DNA Sequencing Companies' Focus on Improving Technologies and Reducing Costs
  - 4.4.1.1. Singular Genomics Systems, Inc. (U.S.)
  - 4.4.1.2. Ultima Genomics, Inc. (U.S.)
  - 4.4.1.3. Element Biosciences (U.S.)
- 4.4.2. Key Market Players' Emphasis on PorTable and Real-Time Sequencing Technologies
4.5. Regulatory Analysis
- 4.5.1. North America
  - 4.5.1.1. U.S.
  - 4.5.1.2. Canada
- 4.5.2. Europe
- 4.5.3. Asia-Pacific
  - 4.5.3.1. China
  - 4.5.3.2. Japan
  - 4.5.3.3. India
- 4.5.4. Latin America
- 4.5.5. Middle East
4.6. Porter's Five Forces Analysis

5. DNA Sequencing Market Assessment-by Offering

5.1. Overview
5.2. Consumables
- 5.2.1. Sample Preparation Kits & Reagents
  - 5.2.1.1. Library Preparation
  - 5.2.1.2. DNA Extraction & Amplification
  - 5.2.1.3. Quality Control
  - 5.2.1.4. Other Kits & Reagents
- 5.2.2. Other Consumables
5.3. Instruments
5.4. Software
5.5. Services

6. Global DNA Sequencing Market Assessment-by Technology

6.1. Overview
6.2. Next-generation Sequencing
- 6.2.1. Sequencing by Synthesis
- 6.2.2. Ion Semiconductor Sequencing
- 6.2.3. Single-molecule Real-Time Sequencing
- 6.2.4. DNA Nanoball Sequencing
- 6.2.5. Other NGS Sequencing Technologies
6.3. Sanger Sequencing & Pyrosequencing

7. DNA Sequencing Market Assessment-by Application

7.1. Overview
7.2. Research & Other Applications
- 7.2.1. Drug Discovery
- 7.2.2. Agricultural & Animal Research
- 7.2.3. Other Applications
7.3. Clinical Applications
- 7.3.1. Oncology
- 7.3.2. Reproductive Health
- 7.3.3. Infectious Diseases
- 7.3.4. Other Clinical Applications

8. DNA Sequencing Market Assessment-by End User

8.1. Overview
8.2. Pharmaceutical & Biotechnology Companies
8.3. Hospitals & Diagnostic Laboratories
8.4. Academic & Research Institutes
8.5. Other End Users

9. DNA Sequencing Market Assessment-by Geography

9.1. Overview
9.2. North America
- 9.2.1. U.S.
- 9.2.2. Canada
9.3. Europe
- 9.3.1. Germany
- 9.3.2. France
- 9.3.3. U.K.
- 9.3.4. Italy
- 9.3.5. Spain
- 9.3.6. Rest of Europe (ROE)
9.4. Asia-Pacific
- 9.4.1. China
- 9.4.2. Japan
- 9.4.3. India
- 9.4.4. Rest of Asia-Pacific (ROAPAC)
9.5. Latin America
- 9.5.1. Brazil
- 9.5.2. Mexico
- 9.5.3. Rest of Latin America (ROLATAM)
9.6. Middle East & Africa (MEA)

10. Competition Analysis

10.1. Overview
10.2. Key Growth Strategies
10.3. Competitive Benchmarking
10.4. Competitive Dashboard
- 10.4.1. Industry Leaders
- 10.4.2. Market Differentiators
- 10.4.3. Vanguards
- 10.4.4. Emerging Companies
10.5. Market Share Analysis (2023)
- 10.5.1. Illumina, Inc. (U.S.)
- 10.5.2. Thermo Fisher Scientific Inc. (U.S.)
- 10.5.3. MGI Tech Co., Ltd. (China)
- 10.5.4. Agilent Technologies, Inc. (U.S.)
- 10.5.5. QIAGEN N.V. (Netherlands)

11. Company Profiles (Company Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis)

11.1. Illumina, Inc. (U.S.)
11.2. Thermo Fisher Scientific Inc.
11.3. QIAGEN N.V.
11.4. Agilent Technologies, Inc.
11.5. MGI Tech Co., Ltd.
11.6. F. Hoffmann-La Roche Ltd
11.7. Revvity, Inc.
11.8. Pacific Biosciences of California Inc.
11.9. Danaher Corporation
11.10. Bio-Rad Laboratories, Inc.
11.11. Oxford Nanopore Technologies Plc.
11.12. Other Companies

12. Appendix

12.1. Available Customization
12.2. Related Reports